Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

Rani Therapeutics (RANI) announced the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability, and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. “The initiation of Phase 1 trial for RT-114 is an important step towards our vision of making oral biologics a reality,” said Talat Imran, Chief Executive Officer of Rani. “As we initiate this trial and advance RT-114 through clinical development, we view this progress as powerful validation of the modality and the unmet need it addresses. We believe that a tolerable and efficacious oral option has the potential to expand access, improve patient experience, and meaningfully reshape the obesity treatment paradigm.”